Business
Bruker Launches de novo Sequencing for Immunopeptidomics, Library-Free dia-PASEF, Mass Dynamics Knowledge Visualization
PaSER™ Novor faster, real-time de novo sequencing for immunopeptidomics Library-free dia-PASEF® analysis with PaSER 2023b proteomics software Partnership
About this update from Bruker Corporation
[{"type":"text","content":"\n\nPaSER™ Novor faster, real-time de novo sequencing for immunopeptidomics\n\n\nLibrary-free dia-PASEF® analysis with PaSER 2023b proteomics software\n\n\nPartnership with Mass Dynamics for 4D-Proteomics™ knowledge visualization\n\n\n CHICAGO--(BUSINESS WIRE)--\nAt the 19th US HUPO, Bruker Corporation (Nasdaq: BRKR) announced important bioinformatics launches for 4D-Proteomics on the timsTOF platform: A novel de novo sequencing algorithm was developed in collaboration with Rapid Novor Inc., using over 1.7 million PASEF data-points to improve accuracy and speed for immunopeptidomics in real-time. The unmatched sensitivity of the timsTOF SCP system coupled to the new PaSER Novor algorithm delivers a significant performance boost for immunopeptidomics, especially for small tumor biopsy samples.\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230306005557/en/timsTOF SCP ultra-high sensitivity MS (Photo: Business Wire)\ndia-PASEF data analysis using library-free TIMS DIA-NN software now features further improved quantification accuracy, while Mass Dynamics graphical visualization and statistical cloud software now seamlessly integrates with 4D-Proteomics dia-PASEF data.\n\nA. PaSER Novor for Immunopeptide Sequencing\n\nWith PaSER Novor, Bruker launches advanced capabilities for immunopeptidomics, developed in collaboration with Rapid Novor Inc., a Canadian software and CRO services company for antibody sequencing.\n\nImmunopeptidomics requires the sequencing of peptides that are not proteolytic in nature from small tumor biopsy samples on the timsTOF SCP ultra-high sensitivity platform. The search space for proteomics database algorithms can become too big for accurate searches, resulting in low reproducibility and long search times. PaSER Novor derives the peptide sequence from fragment ion spectra de novo after training with over 1.7 million timsTOF data points for real-time results using the GPU-enabled Bruker PaSER proteomics software platform.\n\nProfessor Tony Purcell, Head Immunoproteomics Laboratory at Monash University, said: “De novo searches have been a critical aspect in my lab’s research for many years. This novel algorithm delivers results with accuracy at the speed of data acquisition and enables immunopeptidomics at scale and in real time. This has major i...